Under a tenth of patients that would benefit from obesity jabs such as Wegovy are able to get them, caution the World Health Organization as it releases its inaugural guidance on the medications.
Considering over a billion people worldwide now classified as obese, it is calling for broader and more equitable access to these injectable treatments.
Based on projections, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a chronic disease that can be treated with comprehensive and continuous support," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major hurdles to broad access to the injections that can help people shift considerable body mass, says the agency.
Weight-Loss Drug Shortage
Even in the present most optimistic outlook, the supply of these medications could only cover approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The recommendation urges countries and companies to widen access, by strategies like voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is due to expire in a number of nations in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs replicate a biological compound to delay gastric emptying, reduce hunger and enhance satiety so users eat less.
Individuals commonly start to lose weight after several weeks of starting on the regular doses.
Research indicates users may see weight return within a year of discontinuing the medication, as their normal food cravings resume.
To be carrying excess weight elevates your risk for developing health problems, like diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity impacts people in every country and was responsible for millions of deaths worldwide in 2024, as per the WHO.
